Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance

J Natl Compr Canc Netw. 2016 May;14(5):503-7. doi: 10.6004/jnccn.2016.0059.


Protein-targeted therapies are expected to selectively kill tumor cells that express the targeted protein biomarker. Although a tumor mass may initially respond to targeted therapies based on expression of the targeted protein, all cells within a tumor may not express the targeted protein above a critical threshold level; therefore, those cells that do not express, or that downregulate expression of, the targeted protein may not be responsive to therapy. The ability to monitor the dynamic expression of these protein biomarkers throughout the course of therapy may allow for treatment to be personalized in real-time in response to the evolving nature of the tumor. This report demonstrates, by monitoring a single patient through multiple therapies, how targeted mass spectrometry is an effective, quantitative method that provides real-time analysis of multiple therapeutically associated targeted proteins that can be used to personalize a patient's treatment strategy throughout the course of care.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cell Proliferation
  • ErbB Receptors / metabolism*
  • Humans
  • Male
  • Receptor, ErbB-2 / metabolism*
  • Signal Transduction
  • Treatment Outcome


  • ErbB Receptors
  • Receptor, ErbB-2